---
title: "Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287117752.md"
description: "Regeneron Pharmaceuticals Inc. (REGN) shares rose 3.24% to $649.76 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.08%, while the Dow Jones Industrial Average rose by 1.31%. Despite the gains, REGN remains 20.87% below its 52-week high of $821.11. Trading volume reached 1.1 million, surpassing its 50-day average of 754,984."
datetime: "2026-05-20T20:46:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287117752.md)
  - [en](https://longbridge.com/en/news/287117752.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287117752.md)
---

# Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Regeneron Pharmaceuticals Inc. (REGN) advanced 3.24% to $649.76 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.08% to 7,432.97 and the Dow Jones Industrial Average rising 1.31% to 50,009.35.

This was the stock's second consecutive day of gains.

Regeneron Pharmaceuticals Inc. closed 20.87% below its 52-week high of $821.11, which the company reached on January 9th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc. (AMGN) rose 0.25% to $331.57, Moderna Inc. (MRNA) rose 5.25% to $48.12, and Gilead Sciences Inc. (GILD) rose 0.15% to $130.69.

Trading volume (1.1 M) eclipsed its 50-day average volume of 754,984.

Data source: Dow Jones Market Data, FactSet. Data compiled May 20, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-20-26 1646ET

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas](https://longbridge.com/en/news/286759146.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Leerink Partners Reiterates "Market Perform" Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)](https://longbridge.com/en/news/286773280.md)
- [Regeneron's Phase 3 Melanoma Trial Shows Numeric PFS Benefit But Misses Statistical Significance](https://longbridge.com/en/news/286662524.md)